BBC, and a line of other media channels, has acknowledged Iconovo and its groundbreaking work with immunotherapy company ISR for the development of inhaled and nasal Covid-19 vaccines. Iconovo will develop the dry-powder formulation of the vaccine for ISR, which will be distributed with Iconovo’s single-use inhaler ICOone.

An inhaled Covid-19 vaccine will have several benefits, such as not requiring medical competence to administer, nor a cooling chain. Read more through the following links:

BBC article
https://www.bbc.com/news/health-57553602

Läkemedelsvärlden article
https://www.lakemedelsvarlden.se/vilka-covid-19-vaccin-kommer-vi-ha-i-framtiden/

Swedish TV4 news feature
https://www.tv4.se/artikel/6Kl39r6VPM2RsPuZcKDMRn/haer-aer-nya-vacciniden-pulver